VANCOUVER, April 24 /PRNewswire-FirstCall/ - QLT Inc. today reported financial results for the first quarter ended March 31, 2007. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.
2007 Q1 Results Sales
Visudyne(R) worldwide sales for the first quarter were $61.2 million, a decrease of 42.7% over the first quarter of 2006. Visudyne sales in the U.S. were $8.4 million, down 72.4% over last year, while sales in the rest of the world were $52.8 million, a decrease of 30.7% over last year. The decline in Visudyne sales during the first quarter was mainly due to continued pressure in the U.S. and new competition in the European market.
Eligard(R) worldwide sales for the first quarter were $41.8 million, up 145.6% from the first quarter of 2006. Eligard sales in the U.S. were $19.5 million, up 341% over last year, while sales in the rest of the world were $22.3 million, an increase of 76.9% over last year.
Earnings Per Share (EPS)/Loss Per Share
EPS was $0.06 in the first quarter, compared to $0.13 a year ago. The decline was primarily due to the reduction in Visudyne sales.
Non-GAAP EPS, which excludes stock option expense and the restructuring charge, was $0.08 for the first quarter. Exhibit 1 provides the detailed reconciliation between GAAP and non-GAAP EPS.
QLT Revenues
The Company's revenues were $32.7 million in the first quarter, down 35.1% from the same period last year. Revenues from Visudyne were $20.6 million in the quarter, down 50.5% from the first quarter last year. QLT's share of profit from Visudyne sales decreased to 24.5% compared to 31.6% in the same period last year.
Research and Development (R&D) Expense
R&D expense in the first quarter was $11.1 million, down $3.3 million from R&D expense in the first quarter last year primarily due to decreased spending on Aczone, lemuteporfin and Atrigel projects.
Selling, General and Administrative (SG&A) Expense
For the first quarter of 2007, SG&A expense was $6.8 million, down $1.0 million from prior year first quarter expense, primarily due to decreased legal expenses associated with the TAP litigation.
Cash and Short-term Investments
The company's cash and short-term investments decreased from $378.1 million to $269.8 million during the first quarter of 2007 primarily due to QLT USA's $112.5 million portion of the TAP litigation settlement.
About QLT
QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R). For more information, visit our web site at www.qltinc.com.
Updated Conference Call Information
QLT Inc. will hold an investor conference call to discuss first quarter 2007 results on Wednesday, April 25 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet at www.qltinc.com. To participate on the call, please dial 1-800-525-6384 (North America) or 780-409-1668 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-365-8354 (North America) or 402-220-2881 (International), access code 4498188.
QLT Inc.-Financial Highlights CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ----------------------------------------------- (In accordance with United States generally accepted accounting principles) Three months ended (In thousands of United States dollars, except March 31, per share information) 2007 2006 ------------------------------------------------------------------------- (Unaudited) Revenues Net product revenue $ 25,116 $ 46,805 Net royalties 7,054 2,962 Contract research and development 248 401 Licensing and milestones 285 244 ------------------------------------------------------------------------- 32,703 50,412 ------------------------------------------------------------------------- Costs and expenses Cost of sales 8,719 10,181 Research and development 11,083 14,373 Selling, general and administrative 6,842 7,818 Depreciation 1,584 1,512 Restructuring charge 576 52 ------------------------------------------------------------------------- 28,804 33,936 ------------------------------------------------------------------------- Operating income 3,899 16,476 Investment and other income (expense) Net foreign exchange gains (losses) 25 (1,362) Interest income 3,904 4,617 Interest expense (1,582) (1,594) Other gains 1,152 - ------------------------------------------------------------------------- 3,499 1,661 ------------------------------------------------------------------------- Income from continuing operations before income taxes 7,398 18,137 Provision for income taxes (2,535) (5,483) ------------------------------------------------------------------------- Income from continuing operations 4,863 12,654 ------------------------------------------------------------------------- Loss from discontinued operations, net of income taxes - (521) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Net income $ 4,863 $ 12,133 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Basic net income per common share Continuing operations $ 0.06 $ 0.14 Discontinued operations - (0.01) ------------------------------------------------------------------------- Net income $ 0.06 $ 0.13 Diluted net income per common share Continuing operations $ 0.06 $ 0.14 Discontinued operations - (0.01) ------------------------------------------------------------------------- Net income $ 0.06 $ 0.13 Weighted average number of common shares outstanding (in thousands) Basic 75,283 90,620 Diluted 75,375 90,659 ------------------------------------------------------------------------- QLT Inc. CONDENSED CONSOLIDATED BALANCE SHEETS ------------------------------------- (In accordance with United States generally accepted accounting principles) March 31, December 31, (In thousands of United States dollars) 2007 2006 ------------------------------------------------------------------------- (Unaudited) ASSETS Current assets Cash and cash equivalents $ 267,586 $ 299,053 Short-term investment securities - 75,163 Restricted cash 2,227 3,916 Accounts receivable 30,775 38,872 Income taxes receivable 3,056 4,049 Inventories 36,966 34,268 Current portion of deferred income tax assets 8,660 8,657 Other 16,709 14,031 ------------------------------------------------------------------------- 365,979 478,009 ------------------------------------------------------------------------- Property, plant and equipment 50,318 50,497 Deferred income tax assets 10,878 9,838 Goodwill 97,225 98,641 Other long-term assets 1,865 2,121 ------------------------------------------------------------------------- $ 526,265 $ 639,106 ------------------------------------------------------------------------- ------------------------------------------------------------------------- LIABILITIES Current liabilities Accounts payable $ 14,898 $ 15,255 Accrued liabilities 6,815 125,805 Income taxes payable 40 29 Accrued restructuring charge 1,325 2,383 Current portion of deferred revenue 9,514 11,508 ------------------------------------------------------------------------- 32,592 154,980 Deferred income tax liabilities 5,835 5,483 Uncertain tax position liability 1,842 - Deferred revenue 2,685 2,929 Long-term debt 172,500 172,500 ------------------------------------------------------------------------- 215,454 335,892 ------------------------------------------------------------------------- SHAREHOLDERS' EQUITY Common shares 710,046 708,206 Additional paid in capital 114,704 114,724 Accumulated deficit (599,587) (603,251) Accumulated other comprehensive income 85,648 83,535 ------------------------------------------------------------------------- 310,811 303,214 ------------------------------------------------------------------------- $ 526,265 $ 639,106 ------------------------------------------------------------------------- ------------------------------------------------------------------------- As at March 31, 2007, there were 75,314,397 issued and outstanding common shares and 5,756,705 outstanding stock options. QLT Inc. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS ---------------------------------------------- 2007 First Quarter Reconciliation of GAAP Earnings to Adjusted Non-GAAP Earnings Exhibit 1 ------------------------------------------------------------------------- Three months Three months ended ended March 31, (In millions of United States March 31, 2007 dollars, except per share 2007 Adjusted information) GAAP Adjustments Non-GAAP(1) ------------------------------------------------------------------------- (Unaudited) Revenues Net product revenue $ 25.1 $ - $ 25.1 Net royalties 7.1 - 7.1 Contract research and development 0.2 - 0.2 Licensing and milestones 0.3 - 0.3 ------------------------------------------------------------------------- 32.7 - 32.7 ------------------------------------------------------------------------- Cost and expenses Cost of sales (8.7) 0.0(a) (8.7) Research and development (11.1) 0.6(a) (10.5) Selling, general and administrative (6.8) 0.3(a) (6.5) Depreciation (1.6) - (1.6) Restructuring charge (0.6) 0.6(b) - ------------------------------------------------------------------------- (28.8) 1.5 (27.3) ------------------------------------------------------------------------- Operating income 3.9 1.5 5.4 Investment and other income (expense) Net foreign exchange gains 0.0 - 0.0 Interest income 3.9 - 3.9 Interest expense (1.6) - (1.6) Other gains 1.2 - 1.2 ------------------------------------------------------------------------- 3.5 - 3.5 Income before income taxes 7.4 1.5 8.9 Provision for income taxes (2.5) (0.2)(c) (2.7) ------------------------------------------------------------------------- Net income $ 4.9 $ 1.3 $ 6.2 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Net income per common share: Basic $ 0.06 $ 0.08 Diluted 0.06 0.08 Weighted average number of common shares outstanding (in millions) Basic 75.3 75.3 Diluted 75.4 75.4 Adjustments: (a) Remove stock based compensation. (b) Remove restructuring charge. (c) Remove the income tax impact of (b). (1) The adjusted non-GAAP financial measures have no standardized meaning under GAAP and are not comparable between companies. Management believes that the adjusted non-GAAP financial measures are useful for the purpose of financial analysis. Management uses these measures internally to evaluate the Company's operating performance before items that are considered by management to be outside of the Company's core operating results. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-aventis.
QLT Inc. is listed on the NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."
A full explanation of how QLT determines and recognizes revenue resulting from Visudyne sales is contained in the financial statements contained in the periodic reports on Forms 10-Q and 10-K, under the heading "Significant Accounting Policies - Revenue Recognition". Visudyne sales are product sales by Novartis under its agreement with QLT.
Certain statements in this press release constitute "forward looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward looking information" within the meaning of the Securities Act (Ontario). Forward looking statements include, but are not limited to: our expectations regarding the future role of Visudyne and statements which contain language such as: "assuming," "prospects," "future," "projects," "expects" and "outlook". Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Factors that could cause actual events or results to differ materially include, but are not limited to: the Company's future operating results are uncertain and likely to fluctuate, currency fluctuations in primary markets might impact financial results, the risk that future sales of Visudyne and Eligard may be less than expected (including as a result of the timing and impact of existing competitive products and/or new products launched by competitors and the level of physician acceptance of Visudyne in combination with other agents), the Company's reliance on third parties for the manufacture and marketing of Visudyne and Eligard, we are still involved in ongoing litigation and the cost of litigation can be unpredictable and may increase our 2007 SG&A expenses and adversely affect financial condition beyond what is currently expected; general economic conditions and other factors described in detail in QLT's Annual Information Form on Form 10 K, quarterly reports on Form 10 Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.
CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Tamara Hicks, Telephone: (604) 707-7000, or 1-800-663-5486, Fax: (604) 707-7001
QLT Inc.CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Tamara Hicks,Telephone: (604) 707-7000, or 1-800-663-5486, Fax: (604) 707-7001
